Shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) have received an average recommendation of “Hold” from the seven research firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $58.75.

A number of equities analysts have issued reports on AIMT shares. Roth Capital started coverage on shares of Aimmune Therapeutics in a report on Monday, November 20th. They set a “buy” rating and a $60.00 price objective on the stock. Zacks Investment Research raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 16th. Wedbush reaffirmed an “ourperform” rating and set a $42.00 price objective on shares of Aimmune Therapeutics in a report on Monday, August 14th. Piper Jaffray Companies lifted their price objective on shares of Aimmune Therapeutics from $38.00 to $60.00 and gave the stock an “overweight” rating in a report on Tuesday, December 5th. Finally, BidaskClub downgraded shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday.

Shares of Aimmune Therapeutics (NASDAQ AIMT) opened at $34.16 on Tuesday. Aimmune Therapeutics has a one year low of $15.97 and a one year high of $38.86.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.09. equities research analysts expect that Aimmune Therapeutics will post -2.54 earnings per share for the current year.

In related news, insider Susan E. Barrowcliffe sold 20,000 shares of the business’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $25.00, for a total value of $500,000.00. Following the transaction, the insider now directly owns 20,000 shares of the company’s stock, valued at approximately $500,000. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Douglas T. Sheehy sold 1,906 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $38.66, for a total transaction of $73,685.96. Following the completion of the transaction, the insider now directly owns 1,906 shares in the company, valued at $73,685.96. The disclosure for this sale can be found here. Insiders have sold a total of 274,986 shares of company stock worth $7,533,100 over the last ninety days. Insiders own 17.59% of the company’s stock.

Large investors have recently modified their holdings of the stock. SG Americas Securities LLC boosted its holdings in shares of Aimmune Therapeutics by 10.1% in the 2nd quarter. SG Americas Securities LLC now owns 5,451 shares of the biotechnology company’s stock worth $112,000 after buying an additional 499 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of Aimmune Therapeutics by 26.6% in the 2nd quarter. Legal & General Group Plc now owns 7,776 shares of the biotechnology company’s stock worth $160,000 after buying an additional 1,634 shares during the last quarter. Voya Investment Management LLC boosted its holdings in shares of Aimmune Therapeutics by 31.2% in the 2nd quarter. Voya Investment Management LLC now owns 15,781 shares of the biotechnology company’s stock worth $324,000 after buying an additional 3,757 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new position in shares of Aimmune Therapeutics in the 2nd quarter worth about $333,000. Finally, Citadel Advisors LLC purchased a new stake in Aimmune Therapeutics during the second quarter valued at about $360,000. 73.34% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This report was reported by American Banking News and is owned by of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.americanbankingnews.com/2017/12/12/aimmune-therapeutics-inc-aimt-given-consensus-recommendation-of-hold-by-analysts.html.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.